Brief: Bergenbio Presents Clinical Data On Bemcentinib In Combination With Docetaxel In Patients With Previously Treated Advanced NSCLC At ASCO Annual Meeting 2022
06/06/2022 17:21
June 6 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN
COMBINATION
WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED
NSCLC AT ASCO ANNUAL MEETING 2022
Source text for Eikon: ID:nWkrc9VxPy
Further company coverage: BGBIO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee